ArticlePloS one2013
Targeted selected reaction monitoring mass spectrometric immunoassay for insulin-like growth factor 1.
Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 45 citations in OpenAlex.
- Solvent Interaction Analysis: A New Lens for Protein Structure and Diagnostics.International journal of molecular sciences · 2026Review
- Differentiation of Common IGF-1 Variants Using HRMS COM Determination with Follow-Up MS/MS Verification.Methods in molecular biology (Clifton, N.J.) · 2022Article
- An antibody-free LC-MS/MS method for the quantification of intact insulin-like growth factors 1 and 2 in human plasma.Analytical and bioanalytical chemistry · 2021Article
- Assuring Consistent Performance of an Insulin-Like Growth Factor 1 MALDImmunoassay by Monitoring Measurement Quality Indicators.Analytical chemistry · 2017Article
- Article
- Development of quantitative mass spectrometric immunoassay for serum amyloid A.Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals · 2016Article
- Article
- Protein-Based Classifier to Predict Conversion from Clinically Isolated Syndrome to Multiple Sclerosis.Molecular & cellular proteomics : MCP · 2016Article
- Development of multiplex mass spectrometric immunoassay for detection and quantification of apolipoproteins C-I, C-II, C-III and their proteoforms.Methods (San Diego, Calif.) · 2015Article
- Quantitative mass spectrometric immunoassay for the chemokine RANTES and its variants.Journal of proteomics · 2015Article
- Towards identification of true cancer biomarkers.BMC medicine · 2014Article
- Advances in Proteomic Technologies and Its Contribution to the Field of Cancer.Advances in medicine · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Insulin-like growth factor 1 (IGF1) is an important biomarker of human growth disorders that is routinely analyzed in clinical laboratories. Mass spectrometry-based workflows offer a viable alternative to standard IGF1 immunoassays, which utilize various pre-analytical preparation strategies. In this work we developed an assay that incorporates a novel sample preparation method for dissociating IGF1 from its binding proteins. The workflow also includes an immunoaffinity step using antibody-derivatized pipette tips, followed by elution, trypsin digestion, and LC-MS/MS separation and detection of the signature peptides in a selected reaction monitoring (SRM) mode. The resulting quantitative mass spectrometric immunoassay (MSIA) exhibited good linearity in the range of 1 to 1,500 ng/mL IGF1, intra- and inter-assay precision with CVs of less than 10%, and lowest limits of detection of 1 ng/mL. The linearity and recovery characteristics of the assay were also established, and the new method compared to a commercially available immunoassay using a large cohort of human serum samples. The IGF1 SRM MSIA is well suited for use in clinical laboratories.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.